Related Experiment Video
Updated: May 28, 2025

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
Published on: April 16, 2019
Prediction of the Extent of Blood-Brain Barrier Transport Using Machine Learning and Integration into the
Berfin Gülave1, Helle W van den Maagdenberg1,2, Luke van Boven1
1Systems Pharmacology and Pharmacy, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Introduction:
The unbound brain-to-plasma partition coefficient (Kp,uu,BBB) is an essential parameter for predicting central nervous system (CNS) drug disposition using physiologically-based pharmacokinetic (PBPK) modeling. Kp,uu,BBB values for specific compounds are however often unavailable, and are moreover time consuming to obtain experimentally. The aim of this study was to develop a quantitative structure-property relationship (QSPR) model to predict the Kp,uu,BBB and to demonstrate how QSPR-model predictions can be integrated into a physiologically-based pharmacokinetic model for the CNS.
Methods:
Rat Kp,uu,BBB values were obtained for 98 compounds from literature or in house historical data. For all compounds, 2D and 3D physico-chemical and structural properties were derived using the Molecular Operating Environment (MOE) software. Multiple machine learning (ML) regression models were compared for prediction of the Kp,uu,BBB, including random forest, support vector machines, K-nearest neighbors, and (sparse-) partial least squares. Finally, we demonstrate how the developed QSPR model predictions can be integrated into a CNS PBPK modeling workflow.
Results:
Among all ML algorithms, a random forest showed the best predictive performance for Kp,uu,BBB on test data with R2 value of 0.61 and 61% of all predictions were within twofold error. The obtained Kp,uu,BBB were successfully integrated into the LeiCNS-PK3.0 CNS PBPK model.
Conclusions:
The developed random forest QSPR model for Kp,uu,BBB prediction was found to have adequate performance, and can support drug discovery and development of novel investigational drugs targeting the CNS in conjunction with CNS PBPK modeling.

